Article

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

2021-01-05

Abstract excerpt

<title>Abstract</title> <p>A combination of plasma phospho-tau (P-tau) and other accessible biomarkers may provide accurate prediction about the risk of developing Alzheimer’s disease (AD) dementia. We examined this in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) who were consecutively recruited in the BioFINDER study (n=340). The results were validated in SCD/MCI participa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 10fbaf1b-ce8f-5fb7-ab58-e7dd211d4acc
DOI: 10.21203/rs.3.rs-134146/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measuresDOI 10.21203/rs.3.rs-134146/v1Read

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity Read

Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adultsSemantic proximity Read

Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studiesSemantic proximity Read

APOE ε4 carriership status enhances age-related changes in Alzheimer’s disease plasma biomarkers concentrationsSemantic proximity Read

Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer’s DiseaseSemantic proximity Read

Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and PrognosticsSemantic proximity Read

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s diseaseSemantic proximity Read

Emerging Biomarkers for Early Detection of Alzheimer’s Disease: A Systematic ReviewSemantic proximity Read

Plasma biomarker levels and cognitive decline in a heterogenous community-based cohort with multiple comorbiditiesSemantic proximity Read

Predicting Preclinical Cognitive Decline Using Plasma P-tau217 and <i>APOE</i> Genotype in 8,582 Individuals From Different Ethnic GroupsSemantic proximity Read